Evidence map›Paper›PMID 28775305›Full record

ArticleScientific reports2017

Selection and characterization of DNA aptamer against glucagon receptor by cell-SELEX.

Guodong Wang, Jun Liu, Ke Chen, Yiling Xu, Bo Liu, Jie Liao, Lei Zhu, Xiaoxiao Hu, Jianglin Li, Ying Pu and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 48 citations in OpenAlex.

  1. Trial
  2. Developing Aptamer-Targeted mRNA for Immunotherapy.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Generation and Selection of Specific Aptamers TargetingInternational journal of molecular sciences · 2022
    Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 3 countries.

Guodong WangXiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Jun LiuXiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Ke ChenXiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Yiling XuXiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Bo LiuXiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Jie LiaoXiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Lei ZhuAnhui Provincial Engineering Research Center for Polysaccharide Drugs, Anhui Province Key Laboratory of Active Biological Macromolecules, School of Pharmacy, Wannan Medical College, Wuhu, 241002, China.
Xiaoxiao HuMolecular Science and Biomedicine Laboratory, State Key Laboratory for Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Biology, and Collaborative Research Center of Molecular Engineering for Theranostics, Hunan University, Changsha, Hunan, 410082, China.
Jianglin LiMolecular Science and Biomedicine Laboratory, State Key Laboratory for Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Biology, and Collaborative Research Center of Molecular Engineering for Theranostics, Hunan University, Changsha, Hunan, 410082, China.
Ying PuXiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Wen ZhongXiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Ting FuMolecular Science and Biomedicine Laboratory, State Key Laboratory for Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Biology, and Collaborative Research Center of Molecular Engineering for Theranostics, Hunan University, Changsha, Hunan, 410082, China.
Huixia LiuXiangya Hospital, Central South University, Changsha, Hunan, 410008, China. lhx900@aliyun.com.
Weihong TanMolecular Science and Biomedicine Laboratory, State Key Laboratory for Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Biology, and Collaborative Research Center of Molecular Engineering for Theranostics, Hunan University, Changsha, Hunan, 410082, China. tan@chem.ufl.edu.ORCID 0000-0002-8066-1524
Central South University · CNHunan University · CNWannan Medical College · CN

Funding

Development of molecular probes for biomedical applicationsR01GM079359 · NIGMS · UNIVERSITY OF FLORIDA · PI TAN, WEIHONG · 2007 to 2016
$2.3M
NIGMS NIH HHS R01 GM079359
6 · The paper itself

Abstract

Excessive secretion of glucagon, a functional insulin antagonist, significantly contributes to hyperglycemia. Glucagon exerts its physiological functions through activation of the glucagon receptor (GCGR). Inhibition of GCGR activity represents a potential therapeutic approach for reducing excess glucose production in diabetes mellitus. Aptamers are short DNA or RNA oligonucleotides evolved from systematic evolution of ligands by exponential enrichment (SELEX). Here, we have successfully selected a DNA aptamer against GCGR by cell-SELEX, which can specifically bind membrane protein of CHO-GCGR cells with a K

Indexed as

AnimalsAptamers, NucleotideCHO CellsCricetulusGlucagonLiverMiceReceptors, GlucagonSELEX Aptamer TechniqueAptamers, NucleotideGlucagonReceptors, Glucagon

Identifiers

PMID28775305
PMCPMC5543139
OpenAlexW2740939607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.